111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
CHA2DS2-VASc 评分可预测无房颤的急性冠状动脉综合征患者经皮冠状动脉介入治疗后的预后
Authors Long X, Jin Q, Jiang L, Chen R, Hu L
Received 1 August 2025
Accepted for publication 25 October 2025
Published 25 November 2025 Volume 2025:21 Pages 1595—1602
DOI https://doi.org/10.2147/TCRM.S551947
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Xiao Long, Qiao Jin, Luping Jiang, Ran Chen, Lu Hu
Department of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People’s Republic of China
Correspondence: Xiao Long, Department of Cardiovascular Medicine, Changsha Central Hospital, No. 161, Shaoshan South Road, Changsha, 410004, People’s Republic of China, Tel +86 0731 85667902, Email longxiaocs@163.com
Purpose: To evaluate the prognostic value of the CHA2DS2-VASc score for 12-month major adverse cardiovascular events (MACE) in Chinese patients with acute coronary syndrome (ACS) without atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).
Patients and Methods: This retrospective study included 992 consecutive ACS patients without AF who underwent PCI from January 2019 to December 2022. Patients were stratified into low- (0– 1), moderate- (2), and high-risk (> 2) groups based on the CHA2DS2-VASc score. The primary endpoint was MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke. Multivariate Cox regression was used to evaluate the association between risk groups and outcomes.
Results: During the 12-month follow-up, MACE occurred in 12.7%, 21.4%, and 28.8% of the low-, moderate-, and high-risk groups, respectively (P< 0.01). After adjusting for confounders, the CHA2DS2-VASc score remained independently associated with MACE (HR=2.27, 95% CI: 1.34– 3.86 for moderate risk; HR=3.83, 95% CI: 1.90– 7.69 for high risk; both P< 0.01).
Conclusion: The CHA2DS2-VASc score independently predicts 12-month MACE in non-AF ACS patients after PCI, with risks 2.27-fold higher in moderate-risk and 3.83-fold higher in high-risk patients compared with low-risk patients. This simple, readily available tool may help identify patients at higher risk for MACE and inform secondary prevention strategies.
Keywords: CHA2DS2-VASc score, acute coronary syndrome, percutaneous coronary intervention, major adverse cardiovascular events, risk stratification
Department of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People’s Republic of China
Correspondence: Xiao Long, Department of Cardiovascular Medicine, Changsha Central Hospital, No. 161, Shaoshan South Road, Changsha, 410004, People’s Republic of China, Tel +86 0731 85667902, Email longxiaocs@163.com
Purpose: To evaluate the prognostic value of the CHA2DS2-VASc score for 12-month major adverse cardiovascular events (MACE) in Chinese patients with acute coronary syndrome (ACS) without atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).
Patients and Methods: This retrospective study included 992 consecutive ACS patients without AF who underwent PCI from January 2019 to December 2022. Patients were stratified into low- (0– 1), moderate- (2), and high-risk (> 2) groups based on the CHA2DS2-VASc score. The primary endpoint was MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke. Multivariate Cox regression was used to evaluate the association between risk groups and outcomes.
Results: During the 12-month follow-up, MACE occurred in 12.7%, 21.4%, and 28.8% of the low-, moderate-, and high-risk groups, respectively (P< 0.01). After adjusting for confounders, the CHA2DS2-VASc score remained independently associated with MACE (HR=2.27, 95% CI: 1.34– 3.86 for moderate risk; HR=3.83, 95% CI: 1.90– 7.69 for high risk; both P< 0.01).
Conclusion: The CHA2DS2-VASc score independently predicts 12-month MACE in non-AF ACS patients after PCI, with risks 2.27-fold higher in moderate-risk and 3.83-fold higher in high-risk patients compared with low-risk patients. This simple, readily available tool may help identify patients at higher risk for MACE and inform secondary prevention strategies.
Keywords: CHA2DS2-VASc score, acute coronary syndrome, percutaneous coronary intervention, major adverse cardiovascular events, risk stratification